Miromatrix Medical Investor Relations Material

Miromatrix Medical Inc. develops a novel technology for bioengineering fully transplantable organs. Its proprietary technology uses a two-step method of decellularization and recellularization designed to remove the porcine cells from the organs obtained from pigs and replace them with unmodified human cells. The company has collaborations with The Mayo Clinic, Mount Sinai Hospital, and The Texas Heart Institute.